Vnitřní lékařství 3/2021

PŘEHLEDOVÉ ČLÁNKY Biomarker GDF-15 v kardiologii E14 | 10. Santema BT, Chan MMY, Tromp J et al. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. Clin Res Cardiol. 2020; 109(3): 331–338. 11. Sharma A, Stevens SR, Lucas J et al. Utility of Growth Differentiation Factor-15, A Mar- ker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF- -ACTION Study. JACC Heart Fail. 2017; 5(10): 724–734. 12. Bouabdallaoui N, Claggett B, Zile MR et al. Growth differentiation factor-15 is not mo- dified by sacubitril/valsartan and is an independent marker of risk in patients with he- art failure and reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2018; 20(12): 1701–1709. 13. Cotter G, Voors AA, Prescott MF et al. Growth differentiation factor 15 (GDF-15) in pa- tients admitted for acute heart failure: results from the RELAX-AHF study. Eur J Heart Fail. 2015; 17(11): 1133–1143. 14. Anand IS, Kempf T, Rector TS et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010; 122(14): 1387–1395. 15. Sunman H, Canpolat U, Yorgun H et al. Association between reverse electrical remo- deling and cardiac fibrosis markers in patients with cardiac resynchronization therapy. Turk Kardiyol Dern Ars. 2018; 46(2): 84–91. 16. Foley PW, Stegemann B, Ng K et al. Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. Eur Heart J. 2009; 30(22): 2749–2757. 17. Hindricks G, Potpara T, Dagres N et al. 2020 ESC Guidelines for the diagnosis and ma- nagement of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020. 18. Hijazi Z, Oldgren J, Lindback J et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and va- lidation study. Lancet. 2016; 387(10035): 2302–2311. 19. Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V et al. Long-termbleeding risk prediction in ‘real world’ patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project. Thromb Haemost. 2017; 117(10): 1848–1858. 20. Wallentin L, Lopes RD, Hanna M et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013; 127(22): 2166–2176. 21. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139–1151. 22. Berg DD, Ruff CT, Jarolim P et al. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENG- AGE AF-TIMI 48. Circulation. 2019; 139(6): 760–771. 23. Esteve-Pastor MA, Rivera-Caravaca JM, Shantsila A et al. Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiab- le Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial. Thromb Hae- most. 2017; 117(12): 2261–2266. 24. Hijazi Z, Oldgren J, Lindback J et al. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018; 39(6): 477–485. 25. Kempf T, Bjorklund E, Olofsson S et al. Growth-differentiation factor-15 impro- ves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J. 2007; 28(23): 2858–2865. 26. Wallentin L, Lindholm D, Siegbahn A et al. Biomarkers in relation to the effects of tica- grelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome pa- tients managed with or without in-hospital revascularization: a substudy from the Pro- spective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2014; 129(3): 293–303. 27. Wallentin L, Lindhagen L, Arnstrom E et al. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. Lancet. 2016; 388(10054): 1903–1911. 28. Wollert KC, Kempf T, Peter T et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007; 115(8): 962–971. 29. Widera C, Pencina MJ, Bobadilla M et al. Incremental prognostic value of biomarkers beyond the GRACE (Global Registry of Acute Coronary Events) score and high-sensiti- vity cardiac troponin T in non-ST-elevation acute coronary syndrome. Clin Chem. 2013; 59(10): 1497–1505. 30. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al. Effects of ranolazine on recu- rrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007; 297(16): 1775–1783. 31. Collet JP, Thiele H, Barbato E et al. 2020 ESC Guidelines for the management of acu- te coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020. 32. Kahli A, Guenancia C, Zeller M et al. Growth differentiation factor-15 (GDF-15) levels are associated with cardiac and renal injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. PLoS One. 2014; 9(8): e105759. 33. Munk PS, Valborgland T, Butt N, Larsen AI. Response of growth differentiation factor-15 to percutaneous coronary intervention and regular exercise training. Scand Cardiovasc J. 2011; 45(1): 27–32. Získejte také nové aktuální informace a kredity v rámci celoživotního vzdělávání ➜ https://online.solen.cz Rádi vám pomáháme v on-line vzdělávání 23 on-line kurzů a kongresů 7200 účastníků 160 přednášek 1340 vydaných certi kátů